Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911700 · ClinicalTrials.gov registry record · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
A NA study of Open Midline Laparotomy, sponsored by C. R. Bard.
- Recruiting
- Registry status
- NA
- Development phase
- 477
- Enrollment target
- 20
- Study locations
NCT03911700: Recruiting NA study of Open Midline Laparotomy, sponsored by C. R. Bard.
NCT03911700 is a NA study of Open Midline Laparotomy that is actively recruiting participants, run by C. R. Bard. The registered enrollment target is 477 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03911700, a NA study of Open Midline Laparotomy, is actively recruiting participants, sponsored by C. R. Bard.
- RECRUITING
- Registry status
- NA
- Development phase
- 477 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Primary Outcome
The primary endpoint of the trial is the occurrence of incisional hernia in each treatment group (Phasix™ Mesh or Control Group)
Conditions Studied
Interventions
- DEVICE Phasix™ Mesh
Study Locations (20)
Missouri
- St. Luke's Hospital - Kansas City
- Cox Health - Springfield
- Washington University - St Louis
California
- Keck Medical Center of USC - Los Angeles
- University of California San Francisco - San Francisco
Connecticut
- Hartford Hospital - Hartford
- St. Francis Hospital and Medical Center - Hartford
Minnesota
- Minneapolis VA Health Care System - Minneapolis
- University of Minnesota - Minneapolis
Nebraska
- Nebraska Medical Center - Omaha
- Nebraska Methodist Hospital - Omaha
Arizona
- Dignity Health - Phoenix
Georgia
- Emory University - Atlanta
Illinois
- OSF Saint Francis Medical Center - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2031-12 |
| Phase | NA |
What NCT03911700 shows while recruiting
NCT03911700 is an interventional study that assigns participants to a tested intervention. The registered 477 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Open Midline Laparotomy appearing as the primary indexed condition, and to 1 intervention - of which Phasix™ Mesh is the first listed.
NCT03911700 names 20 study sites across 14 states, led by Missouri, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03911700 about?
NCT03911700 is a clinical study titled "Prophylactic Reinforcement of Ventral Abdominal Incisions Trial". This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
What is the current status of trial NCT03911700?
This trial is currently recruiting. It is a NA study. The enrollment target is 477 participants. The study started on 2019-12-12. Estimated completion is 2031-12.
What conditions does trial NCT03911700 study?
This clinical trial studies the following conditions: Open Midline Laparotomy.
What interventions are being tested in trial NCT03911700?
The interventions under investigation include: Phasix™ Mesh (DEVICE).
Who is sponsoring clinical trial NCT03911700?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03911700 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03911700's enrollment target sits among peer trials
477 219th of 2000 higher than 1,782 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06997497 · 477 participants · Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI